##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 8 (2025)

Pitstop approach: diabetologist referral and quality of care in patients with type 2 diabetes – a Swiss longitudinal study

Cite this as:
Swiss Med Wkly. 2025;155:4031
Published
25.08.2025

Summary

STUDY AIMS: Patients with type 2 diabetes mellitus are typically managed in primary care settings, but management has become more complex in recent years due to modern therapeutic options. There is a paucity of data on the role of a one-off referral to an outpatient diabetes centre (a “pitstop” approach) in improving the quality of diabetes care.

METHODS: This was a retrospective study of patients with type 2 diabetes mellitus who were referred to an outpatient diabetes centre at a regional hospital in Switzerland between 1 January 2019 and 31 December 2020. The primary outcome was the change in glycated haemoglobin (HbA1c) between the first and last consultation. Secondary endpoints included changes in body weight, blood pressure, low-density lipoprotein cholesterol and use of antidiabetic medications.

RESULTS: At a median follow-up of 5.1 months (interquartile range [IQR] 3.0–9.1) after referral to an outpatient diabetes centre, haemoglobin A1c improved from 8.6% / 70.5 mmol/mol to 7.3% / 56.3 mmol/l (difference −1.28% / −14.2 mmol/l; 95% confidence interval [CI] −1.50 to −1.05), body weight decreased from 91.0 kg to 88.0 kg (difference −3.93; 95% CI −4.9 to −3.0) and systolic blood pressure values decreased by 1.6 mm Hg (95% CI −2.7 to −0.5), while low-density lipoprotein cholesterol levels remained unchanged. Compared to baseline, the pitstop approach resulted in decreased prescriptions for sulfonylureas (11.0% vs 2.8%) and dipeptidyl peptidase-4 inhibitors (31.4% vs 20.0%), but increased prescriptions for sodium-glucose cotransporter 2 (SGLT2) inhibitors (15.3% vs 27.5%) and glucagon-like peptide-1 (GLP1) receptor agonists (13.7% vs 46.3%).

CONCLUSION: A short-term intervention by an outpatient diabetes clinic was associated with significant improvements in glycaemic control and body weight in patient with type 2 diabetes. It promoted a shift towards modern antidiabetic medications with proven cardiorenal protective effects.

References

  1. 1. Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2020;162:108072. https://doi.org/10.1016/j.diabres.2020.108072
  2. 2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157:107843. https://doi.org/10.1016/j.diabres.2019.107843
  3. 3. Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107–11. doi: https://doi.org/10.2991/jegh.k.191028.001
  4. 4. Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C. Macrovascular Complications in Patients with Diabetes and Prediabetes. BioMed Res Int. 2017;2017:7839101. 10.1155/2017/7839101
  5. 5. Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019 Dec;26 2_suppl:25–32. doi: https://doi.org/10.1177/2047487319878371
  6. 6. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017 Jun;389(10085):2239–51. doi: https://doi.org/10.1016/S0140-6736(17)30058-2
  7. 7. Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular Complications of Type 2 Diabetes Mellitus. Curr Vasc Pharmacol. 2020;18(2):117–24. doi: https://doi.org/10.2174/1570161117666190502103733
  8. 8. Dietrich I, Braga GA, de Melo FG, da Costa Silva Silva AC. The Diabetic Foot as a Proxy for Cardiovascular Events and Mortality Review. Curr Atheroscler Rep. 2017 Oct;19(11):44. doi: https://doi.org/10.1007/s11883-017-0680-z
  9. 9. Call JT, Cortés P, Harris DM. A practical review of diabetes mellitus type 2 treatment in primary care. Rom J Intern Med. 2022 Mar;60(1):14–23. doi: https://doi.org/10.2478/rjim-2021-0031
  10. 10. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021 Jan;372:m4573. doi: https://doi.org/10.1136/bmj.m4573
  11. 11. Sharma A, Verma S. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Can J Diabetes. 2020 Feb;44(1):93–102. doi: https://doi.org/10.1016/j.jcjd.2019.09.003
  12. 12. Standl E, Schnell O. Treatment paradigm shifting implications of recent cardiovascular outcome trials: core insights on the brink of the 2020ies. Diabetes Res Clin Pract. 2020 Mar;161:108054. doi: https://doi.org/10.1016/j.diabres.2020.108054
  13. 13. Avnat E, Chodick G, Shalev V. Identifying Profiles of Patients With Uncontrolled Type 2 Diabetes Who Would Benefit From Referral to an Endocrinologist. Endocr Pract. 2023 Nov;29(11):855–61. doi: https://doi.org/10.1016/j.eprac.2023.08.002
  14. 14. Zarora R, Immanuel J, Chivese T, MacMillan F, Simmons D. Effectiveness of Integrated Diabetes Care Interventions Involving Diabetes Specialists Working in Primary and Community Care Settings: A Systematic Review and Meta-Analysis. Int J Integr Care. 2022 May;22(2):11. 10.5334/ijic.6025
  15. 15. Hoffman AF, Roberson CL, Cohen P, Jackson VL, Yeatts J, Gregory P, et al. Improving glycemic control in diabetes through virtual interdisciplinary rounds. Am J Manag Care. 2024 Mar;30(3):e78–84. doi: https://doi.org/10.37765/ajmc.2024.89518
  16. 16. Christ E, Czock A, Renström F, Ammeter T, Ebrahimi F, Zechmann S, et al. Evaluation of type 2 diabetes care management in nine primary care practices before and after implementation of the Criteria of Good Disease Management of Diabetes established by the Swiss Society of Endocrinology and Diabetology. Swiss Med Wkly. 2022 Jul;152(2930):w30197. doi: https://doi.org/10.4414/SMW.2022.w30197
  17. 17. Vlacho B, Simarro FL, Mata-Cases M, Miravet S, Escribano-Serrano J, Asensio D, et al. Adherence to antidiabetic treatment among patients managed in primary care centres in Spain: the INTENSE study. Prim Care Diabetes. 2022 Dec;16(6):760–7. doi: https://doi.org/10.1016/j.pcd.2022.10.004
  18. 18. Meier R, Valeri F, Senn O, Rosemann T, Chmiel C. Quality performance and associated factors in Swiss diabetes care - A cross-sectional study. PLoS One. 2020 May;15(5):e0232686. doi: https://doi.org/10.1371/journal.pone.0232686
  19. 19. McAlister FA, Majumdar SR, Eurich DT, Johnson JA. The effect of specialist care within the first year on subsequent outcomes in 24,232 adults with new-onset diabetes mellitus: population-based cohort study. Qual Saf Health Care. 2007 Feb;16(1):6–11. doi: https://doi.org/10.1136/qshc.2006.018648
  20. 20. Malik RA, Hwu CM, Jammah AA, Arteaga-Díaz JM, Djaballah K, Pilorget V, et al. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: an international, multicentre, 12-month, prospective observational study. Diabetes Obes Metab. 2024 Jul;26(7):2811–9. doi: https://doi.org/10.1111/dom.15599
  21. 21. Khanna A, Bush AL, Swint JM, Peskin MF, Street RL Jr, Naik AD. Hemoglobin A1c improvements and better diabetes-specific quality of life among participants completing diabetes self-management programs: a nested cohort study. Health Qual Life Outcomes. 2012 May;10(1):48. 10.1186/1477-7525-10-48
  22. 22. Setji TL, Page C, Pagidipati N, Goldstein BA. DIFFERENCES IN ACHIEVING HBA1C GOALS AMONG PATIENTS SEEN BY ENDOCRINOLOGISTS AND PRIMARY CARE PROVIDERS. Endocr Pract. 2019 May;25(5):461–9. doi: https://doi.org/10.4158/EP-2018-0405
  23. 23. Rudofsky G, Catarig AM, Favre L, Grau K, Häfliger S, Thomann R, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021 Aug;178:108931. doi: https://doi.org/10.1016/j.diabres.2021.108931
  24. 24. Yale JF, Catarig AM, Grau K, Harris S, Klimek-Abercrombie A, Rabasa-Lhoret R, et al. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab. 2021 Oct;23(10):2269–78. doi: https://doi.org/10.1111/dom.14468
  25. 25. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov;45(11):2753–86. doi: https://doi.org/10.2337/dci22-0034
  26. 26. American Diabetes Association. Standards of Care in Diabetes-2023 Abridged for Primary Care Providers. Clin Diabetes. 2022;41(1):4–31.
  27. 27. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923–1049. doi: https://doi.org/10.1016/j.eprac.2022.08.002
  28. 28. Sousa Santos F, Tavares Bello C, Roque C, Capitão R, Castro Fonseca R, Limbert C, et al. The Effect of Changing Regular Care Provider in Type 2 Diabetes Mellitus: A Retrospective Study. Acta Med Port. 2019 Sep;32(9):580–7. doi: https://doi.org/10.20344/amp.11304
  29. 29. Gastaldi G, Lucchini B, Thalmann S, Alder S, Laimer M, Brändle M, et al.; Working group of the SGED/SSED. Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). Swiss Med Wkly. 2023 Apr;153(4):40060. doi: https://doi.org/10.57187/smw.2023.40060
  30. 30. ElSayed NA, Aleppo G, Bannuru RR, Beverly EA, Bruemmer D, Collins BS, et al.; American Diabetes Association Professional Practice Committee. Introduction and Methodology: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan;47 Supplement_1:S1–4. doi: https://doi.org/10.2337/dc24-SINT
  31. 31. Schimke KE, Renström F, Meier S, Stettler C, Brändle M; SwissDiab Study Group. Compliance with guidelines for disease management in diabetes: results from the SwissDiab Registry. BMJ Open Diabetes Res Care. 2018 Feb;6(1):e000454. doi: https://doi.org/10.1136/bmjdrc-2017-000454
  32. 32. Corcillo A, Pivin E, Lalubin F, Pitteloud N, Burnier M, Zanchi A. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices. Swiss Med Wkly. 2017 Jul;147(2728):w14459.
  33. 33. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018 Feb;68(2):305–15. doi: https://doi.org/10.1016/j.jhep.2017.11.013
  34. 34. Maitra NS, Mahtta D, Navaneethan S, Vaughan EM, Kochar A, Gulati M, et al. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 Jun;24(6):689–98. doi: https://doi.org/10.1007/s11886-022-01694-5
  35. 35. Fernando K, Bain SC, Holmes P, Jones PN, Patel DC. Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review. Diabetes Ther. 2021 Sep;12(9):2267–88. doi: https://doi.org/10.1007/s13300-021-01116-9
  36. 36. Hao R, Myroniuk T, McGuckin T, Manca D, Campbell-Scherer D, Lau D, et al. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study. BMC Prim Care. 2022 May;23(1):124. doi: https://doi.org/10.1186/s12875-022-01731-w
  37. 37. Marasinghe DH, Butalia S, Garies S, Drummond N, Kim JW, Senior PA. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes. Can J Diabetes. 2022 Jul;46(5):487–94. doi: https://doi.org/10.1016/j.jcjd.2022.02.002
  38. 38. Antonelli D, Rabkin Y, Turgeman Y, Jabaren M. Type 2 Diabetes Mellitus: GLP1 Receptor Agonists and SGLT2 Inhibitors in Patients Referred to Ambulatory Consultant Cardiology Clinics. Isr Med Assoc J. 2023 Feb;25(2):143–6.
  39. 39. Mingrone G, Castagneto-Gissey L, Bornstein SR. New Horizons: Emerging Antidiabetic Medications. J Clin Endocrinol Metab. 2022 Nov;107(12):e4333–40. doi: https://doi.org/10.1210/clinem/dgac499
  40. 40. Qiao Q, Grandy S, Hiller J, Kostev K. Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany. PLoS One. 2016 Mar;11(3):e0152281. doi: https://doi.org/10.1371/journal.pone.0152281
  41. 41. Perera P, O’Donnabhain R, Fazio T, Johnson D, Lange P. ‘A Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Service’. Clin Med Insights Cardiol. 2022 Oct;16:11795468221133607. 10.1177/11795468221133607
  42. 42. Chawla K, Furlong R, Kamo N, Gerbino I, Smith D, Blackmore C. Clinical spotlight intervention to accelerate translation of evidence-based practices in primary care. BMJ Open Qual. 2022 Dec;11(4):e002032. doi: https://doi.org/10.1136/bmjoq-2022-002032
  43. 43. Blanchard M. Closing the gap between medical knowledge and patient outcomes through new training infrastructure. Trans Am Clin Climatol Assoc. 2023;133:119–35.
  44. 44. Winpenny EM, Miani C, Pitchforth E, King S, Roland M. Improving the effectiveness and efficiency of outpatient services: a scoping review of interventions at the primary-secondary care interface. J Health Serv Res Policy. 2017 Jan;22(1):53–64. doi: https://doi.org/10.1177/1355819616648982